SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

Launched by THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SCG142 TCR-T cells for patients with advanced cancers linked to the human papillomavirus (HPV). These cancers include cervical cancer, head and neck cancers, and several others. The trial is in its first phase, which means it's focused on understanding how safe and effective this treatment is for people with these specific types of cancer. The study is currently recruiting participants who are at least 18 years old and have measurable tumors related to HPV.

To be eligible for the trial, participants must have a certain level of health, as indicated by a performance status score, and must not have serious infections or other medical conditions that could interfere with the treatment. If someone joins the trial, they can expect close monitoring and support from the medical team as they receive this new therapy. This is an exciting opportunity for patients looking for new treatment options, especially if standard treatments have not been effective.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Greater than or equal to 18 years of age
• • 2. HPV associated carcinomas
• • 3. Patients must have at least one measurable lesion defined by RECIST 1.1
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Key Exclusion Criteria:
• • 1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
• • 2. Patients with active autoimmune diseases.
• • 3. Patient has a known active Hepatitis B or Hepatitis C.
• • 4. Other severe medical conditions that may limit subject\'s participation in this trial.